Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had mixed news, with upcoming clinical data offering a potential catalyst while a wave of analyst downgrades and price-target cuts may weigh on investor sentiment.

• Positive Sentiment: Alnylam plans to present five-year HELIOS-B results and additional clinical and real-world evidence on AMVUTTRA (vutrisiran) at conferences in November. The presentations could provide new information about the treatment’s potential, though the announcement did not include new study results. Alnylam conference presentation announcement
• Negative Sentiment: Analyst sentiment weakened: Raymond James cut its rating from Strong Buy to Outperform, while Bernstein moved from Outperform to Market Perform. Raymond James downgrade Bernstein downgrade
• Negative Sentiment: Price expectations have also been trimmed: the consensus target fell 13.64% to $325.18, and Truist lowered its target to $225 from $315 while cutting its rating to Hold. Although the targets remain above the share price cited in the reports, the reductions signal increased caution. Consensus target reduction